<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="429">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155566</url>
  </required_header>
  <id_info>
    <org_study_id>A5481125</org_study_id>
    <secondary_id>IRIS LATAM</secondary_id>
    <nct_id>NCT05155566</nct_id>
  </id_info>
  <brief_title>Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.</brief_title>
  <official_title>Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE/ HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) Advanced/Metastatic Breast Cancer In Real World Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      To describe patient demographics, clinical characteristics, treatment patterns and clinical&#xD;
      outcomes of adult female patients who have received palbociclib combination treatments as&#xD;
      first line therapy, regardless of combination partner and labelled use in real world settings&#xD;
      across Latin America.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of patients demographics receiving Palbociclib</measure>
    <time_frame>Day 1 of treatment to date of latest follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical characteristics of patients receiving Palbociclib</measure>
    <time_frame>Day 1 of treatment to date of latest follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adjuvant therapies received for the treatment of early or locally advanced breast cancer (Stages 0-IIIa)</measure>
    <time_frame>From the initial diagnosis to the metastatic disease (From data collected retrospectively for 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To describe treatments received in the advanced/ metastatic setting, before and after palbociclib combination use.</measure>
    <time_frame>From the initial diagnosis in the metastatic disease (From data collected retrospectively for 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Reduced Doses of Palbociclib</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Dose interruption of Palbociclib</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With discontinuation of Palbociclib</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Delay Doses of Palbociclib</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supportive therapies received by patients while receiving palbociclib combination treatments</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who are progression free at multiple intervals (e.g.12, 18 months)</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with Objective response rate (ORR)</measure>
    <time_frame>June 2019 to September 2019</time_frame>
    <description>Colombia was the last country starting July 2020 and finalized October 2020</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>Proportion of patients alive 1- and 2-year post palbociclib combination initiation - depending on availability of follow-up data</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">847</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
    <description>HR + /HER2- Advanced/Metastatic Breast Cancer patients in Latin America</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective medical data review of patients who have received palbociclib combination&#xD;
        treatments as first line treatment regardless of combination partner and labelled use in&#xD;
        Argentina, Chile, Peru, Mexico and a combined sample in Costa Rica and Panama.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Physician inclusion criteria:&#xD;
&#xD;
          -  Oncologist or gynecologist.&#xD;
&#xD;
          -  Responsible for treating â‰¥4-10 (depending on country) ABC/MBC patients who meet the&#xD;
             eligibility criteria.&#xD;
&#xD;
          -  Agrees to participate in the study and complete the case report forms (CRFs) within&#xD;
             the data collection period.&#xD;
&#xD;
        Patient inclusion criteria:&#xD;
&#xD;
          -  HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.&#xD;
&#xD;
          -  Received palbociclib as a first line therapy.&#xD;
&#xD;
          -  No prior or current enrolment in an interventional clinical trial for ABC/MBC.&#xD;
&#xD;
          -  Minimum of six months of follow up data since palbociclib initiation.&#xD;
&#xD;
        Physician exclusion criteria:&#xD;
&#xD;
          -  Qualified less than 2 years ago or more than 35 years ago.&#xD;
&#xD;
          -  Participated in observational research for ABC/MBC in the last 3 months.&#xD;
&#xD;
          -  Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase&#xD;
             inhibitor as first line therapy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer country office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelphi Mill, Bollington, Cheshire, SK10 5JB, UK</name>
      <address>
        <city>Bollington</city>
        <state>Chesshire</state>
        <zip>SK105JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A5481125</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human epidermal growth factor receptor 2 negative (HER2-)</keyword>
  <keyword>hormone receptor positive (HR+)</keyword>
  <keyword>advanced breast cancer (ABC)</keyword>
  <keyword>metastatic breast cancer (MBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

